CROI 2010
CROI 2010: HIV Raises Lung Cancer Risk, but Smoking Is a Much Stronger Predictor
- Details
- Category: Cancer/Malignancies
- Published on Friday, 26 February 2010 12:57
- Written by Liz Highleyman
HIV infection is significantly associated with lung cancer, increasing the risk by nearly 2-fold, but this was far overshadowed by tobacco smoking, which raised the risk by almost 10-fold, according to a study presented last week at the 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) in San Francisco. Smoking-related risk declined over time after quitting, but never fell to the level of people who never smoked.
CROI 2010: Leakage of Gut Bacteria Linked to Poor Hepatitis C Treatment Response in HIV/HCV Coinfected Patients
- Details
- Category: HIV/HCV Coinfection
- Published on Friday, 26 February 2010 12:57
- Written by Liz Highleyman
HIV/HCV coinfected individuals who did not respond well to interferon-based therapy for hepatitis C showed evidence of greater microbial translocation -- leakage of bacteria due to HIV damaging the gut -- than early responders, although T-cell activation did not differ, according to a poster presentation at the 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) last week in San Francisco.
CROI 2010: Treatment Intensification with Maraviroc (Selzentry) Did Not Raise CD4 Cell Counts in Small Study
- Details
- Category: HIV Treatment
- Published on Tuesday, 23 February 2010 12:57
- Written by Liz Highleyman
Adding the CCR5 antagonist maraviroc (Selzentry) to an antiretroviral regimen that is already fully suppressing HIV viral load did not produce larger CD4 cell gains among people whose immune recovery was stalled, according to a small study presented at the 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) last week in San Francisco. Maraviroc did, however, appear to dampen immune activation.
CROI 2010: Investigational Drug TBR-652 Demonstrates Dual Activity against CCR5 and CCR2 Co-receptors
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 23 February 2010 12:57
- Written by Liz Highleyman
Tobira Therapeutics' investigational CCR5 antagonist TBR-652 was shown to have potent anti-HIV activity and it appeared safe and well-tolerated in its first small trial in people with HIV, researchers reported last week at the 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) in San Francisco. The drug also blocked CCR2, suggesting it might be useful as an anti-inflammatory agent.
CROI 2010: Hepatitis C Virus Can Survive in Syringes Up to 2 Months under Favorable Conditions
- Details
- Category: HCV Prevention
- Published on Tuesday, 23 February 2010 00:00
- Written by Liz Highleyman
Hepatitis C virus (HCV) can survive under certain conditions for prolonged periods in syringes used to inject drugs, thereby increasing the potential for HCV transmission, researchers reported at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last week in San Francisco. These findings are important for shaping needle exchange policies and practices.
Web Design and Development by